Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead product candidates include ORKA-001, which targets the p19 subunit of interleukin-23 and is in a Phase 2a trial for PsO, and ORKA-002, which targets interleukin-17A and interleukin-17F and is in a Phase 2 trial for PsO, psoriatic arthritis, and related conditions. The company is also developing ORKA-003 for an undisclosed pathway and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka is headquartered in Menlo Park, California.

Oruka Therapeutics, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol ORKA. Its shares trade in United States Dollars (USD). As a Nasdaq-listed company, Oruka is subject to the reporting and governance requirements of the U.S. Securities and Exchange Commission, providing transparency to investors. The company's listing on a major U.S. exchange facilitates liquidity and access for institutional and retail investors interested in the biotechnology sector.

Oruka Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it engages in the research and development of biologic drugs—in this case, monoclonal antibody therapeutics—for inflammatory and immunology indications. The company's focus on novel antibody treatments places it among clinical-stage biopharmaceutical firms that aim to address unmet medical needs in chronic inflammatory diseases like psoriasis and psoriatic arthritis.

Oruka Therapeutics, Inc. is headquartered in Menlo Park, California, in the United States. The company primarily serves the U.S. market, as indicated by its country and region designation. Its clinical trials for lead candidates ORKA-001 and ORKA-002 are likely conducted in the U.S., targeting patients with psoriasis and other inflammatory conditions. While the company may eventually expand globally, its current operations and development activities are centered in the United States.

Oruka Therapeutics' pipeline includes several monoclonal antibody candidates. ORKA-001 targets the p19 subunit of interleukin-23 and is in a Phase 2a trial for psoriasis. ORKA-002 targets interleukin-17A and interleukin-17F and is in a Phase 2 trial for psoriasis, psoriatic arthritis, and related conditions. The company also has ORKA-003, which targets an undisclosed pathway, and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. All candidates are in clinical-stage development, with no approved products yet. The company focuses on inflammatory and immunology indications.